Published in Hepatogastroenterology on September 20, 1996
Protective effect of ischemic preconditioning on cold preservation and reperfusion injury associated with rat intestinal transplantation. Ann Surg (2001) 0.97
Anastomotic healing in a small bowel transplantation model in the rat. World J Surg (2003) 0.78
Protective effect of sodium nitroprusside on the rat small intestine transplanted mucosa. Biochem Res Int (2015) 0.75
Evolution of liver transplantation. Hepatology (1982) 19.54
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Kidney transplantation under FK 506. JAMA (1990) 7.45
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med (2005) 3.13
Fungal infections in liver transplant recipients. Transplantation (1985) 3.07
A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Liver transplantation in adults. Hepatology (1982) 2.89
Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Hypothalamic-pituitary-gonadal dysfunction in men using cimetidine. N Engl J Med (1979) 2.61
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Liver transplantation for type IV glycogen storage disease. N Engl J Med (1991) 2.31
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Clinical course after liver transplantation in patients with sarcoidosis. Ann Intern Med (1993) 2.29
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol (1988) 2.21
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
Acute liver failure. Lancet (1995) 2.09
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Treatment of fibrolamellar hepatoma with partial or total hepatectomy and transplantation of the liver. Surg Gynecol Obstet (1986) 2.07
Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology (1981) 2.07
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
The use of interferon for the treatment of viral hepatitis in pediatric liver transplant recipients. J Okla State Med Assoc (1995) 2.02
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Biliary Excretion of Cyclosporine in Liver Transplant Patients. Transplant Proc (1985) 1.98
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg (1988) 1.89
Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88